An Ancillary Study Protocol to GSK's Phase IIb Malaria Vaccine Trial Entitled "Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age"

Malaria Clinical Trial

Official title:

An Ancillary Study Protocol to GlaxoSmithKline Phase IIb RTS,S/AS01E Malaria Vaccine Trial (Study Number 204889 [MALARIA-094]) Entitled, "Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age"

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03281291
• Other study ID #: 206213
• Status: Completed
• Start date: November 19, 2018
• Est. completion date: April 22, 2022

Study information

• Verified date: February 2024
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of the proposed amplicon sequencing and genotyping study is to assess vaccine efficacy against clinical and asymptomatic malaria infection using ultra-sensitive molecular amplification and sequencing methodology to detect Plasmodium falciparum (P. falciparum) parasites from serial blood samples to be collected from children immunized with the primary and yearly booster immunizations of the RTS,S/AS01E vaccine as part of their participation in Protocol MALARIA-094 (parent clinical study protocol). Genomic analysis will be performed on parasites from blood spot samples collected from children aged 5 17 months immunized with RTS,S/AS01E on different dosage and schedule regimens under the parent clinical study protocol.

Description:

This genotyping study of malaria parasites collected from serial blood samples following RTS,S/AS01E immunization will assess vaccine efficacy using molecular genetic data to identify first infections following vaccination, and to distinguish new from existing infections, using an amplicon sequencing-based strategy: deep sequencing of small, highly variable regions of the parasite genome to allow for both:

1. Highly sensitive detection of parasitemia (analogous to conventional polymerase chain reaction [PCR]-based detection), and

2. Identification of genetically distinct parasite populations within or between affected individuals.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1500
• Est. completion date: April 22, 2022
• Est. primary completion date: April 22, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 5 Months to 17 Months

Eligibility

Inclusion Criteria:

• Subjects' parent(s)/LAR(s) who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. return for follow-up visits).

• Signed or thumb-printed and witnessed informed consent obtained from the parent(s)/LAR(s) of the subject prior to performance of any study specific procedure. Where parent(s)/LAR(s) are illiterate, the consent form will be countersigned by an independent witness.

• A male or female between, and including, five and 17 months of age at the time of the first vaccination.

• Healthy subjects as established by medical history and clinical examination before entering into the study.

• Previously received three documented doses of diphtheria, tetanus, pertussis, hepatitis B vaccine (DTPHepB), and at least three doses of oral polio vaccine.

Exclusion Criteria:

• Child in care.

• Use of a drug or vaccine that is not approved for that indication (by one of the following regulatory authorities: Food and Drug Administration [FDA; USA] or European Union member state or WHO [with respect to prequalification]) other than the study vaccines during the period starting 30 days before the first dose of study vaccines (Day -29 to Day 0), or planned use during the study period.

• Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.

• Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting six months prior to the first vaccine dose. For corticosteroids, this will mean prednisone (0.5 mg/kg/day (for pediatric subjects) or equivalent. Inhaled and topical steroids are allowed.

• Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting seven days before each dose and ending seven days after each dose of vaccine administration.

• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).

• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).

• Family history of congenital or hereditary immunodeficiency.

• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.

• History of anaphylaxis post-vaccination.

• History of any, or documented, serious adverse reaction to rabies vaccination.

• Contraindication to rabies vaccination (Rabipur is contraindicated in subjects with an history of a severe hypersensitivity to any of the ingredients in the vaccine. Note that the vaccine contains polygeline and residues of chicken proteins, and may contain traces of neomycin, chlortetracycline and amphotericin B).

• Major congenital defects.

• Serious chronic illness.

• Children with a past history of a neurological disorder or atypical febrile seizure (a febrile seizure is atypical if it meets one of the following criteria: not associated with fever; lasts > 5 minutes; focal (not generalized); followed by transient or persistent neurological abnormality; occurs in a child < 6 months of age).

• Acute disease and/or fever at the time of enrolment.

• Fever is defined as temperature = 37.5°C/99.5°F for oral, axillary or tympanic route, or = 38.0°C/100.4°F for rectal route.

• Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.

• Administration of immunoglobulins and/or any blood products during the period starting three months before the first dose of study vaccine or planned administration during the study period.

• Moderate or severe malnutrition at screening defined as weight for age or weight for height Z-score < -2.

• Hemoglobin concentration < 8 g/dl at screening.

• Same sex twins (to avoid misidentification).

• Maternal death.

• Prior receipt of an investigational malaria vaccine.

Related Conditions & MeSH terms

• Malaria

Locations

Country	Name	City	State
Ghana	GSK Investigational Site	Kumasi
Kenya	GSK Investigational Site	Kisumu

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Ghana,  Kenya, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to the first new malaria infection.	New malaria infection from genomic analysis of blood spots detected from active screening of infection or passive detection of clinical malaria.	Up to 20 months post Dose 1
Primary	Number of new malaria infections during a specified follow-up period.	New malaria infection from genomic analysis of blood spots detected from active screening of infection or passive detection of clinical malaria.	Up to 20 months post Dose 1